A number of clinical and preclinical programs are in development featuring our tetravalent bispecific ICE® (innate cell engager) molecules based on the ROCK® (Redirected Optimized Cell Killing) platform, and have already shown a favorable safety profile and promising signs of therapeutic efficacy.
AFM13 is a first-in-class ICE® (innate cell engager) molecule that has the potential to deliver clinically meaningful benefits to patients with CD30+ lymphomas.1
AFM24 is an EGFR-binding ICE® (innate cell engager) molecule that kills EGFR-expressing tumors, and through ADCC and ADCP, holds promise to treat all patient subtypes with a more acceptable safety profile compared with current advanced treatments, while remaining immune to the challenge of resistance.2
Expanding our pipeline are AFM28, Roivant-partnered AFM32, a Genentech-partnered ICE® (innate cell engager) molecule, and several ICE® (innate cell engager) + NK-cell combinations—all at the pre-IND stage.
Innate Cell Engagers
ICE® Molecules: Mechanism of Action
ADCC=antibody-dependent cellular cytotoxicity; ADCP=antibody-dependent cellular phagocytosis; EGFR=epidermal growth factor receptor; IND=investigational new drug; NK=natural killer.
References: 1. Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024-4031. 2. Reusch U, Damrat M, Wingert S, et al. AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies. Poster presented at: American Association for Cancer Research (AACR) Annual Meeting; June 22-24, 2020; Virtual. Poster 5659.